Clinical Trials on Multiple Sclerosis-Relapsing-Remitting in Peru

Total 39 results

Biogen

Completed

Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis

Russian Federation
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis

Relapsing-remitting Multiple Sclerosis

Spain, Czechia, Bulgaria, Serbia, Russian Federation, Ukraine, Poland, Slovakia
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) (GLOW)

Relapsing-Remitting Multiple Sclerosis

United States, Albania, Belarus, Bosnia and Herzegovina, Bulgaria, Croatia, Estonia, Georgia, Greece, Latvia, Macedonia, The Former Yugoslav Republic of, Mexico, Moldova, Republic of, Montenegro, Poland, Romania, Russian... and more
Biogen
AbbVie

Terminated

Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 (EXTEND)

Multiple Sclerosis | Relapsing-Remitting Multiple Sclerosis

United States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
Biogen
AbbVie

Completed

Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis ((DECIDE))

Relapsing-Remitting Multiple Sclerosis

Sweden, United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Ukraine, Denmark, Finland, Romania, Canada, France, Hungary, Israel, Switzerland, Serbia, India, Mexico, Poland, Georgia, Ireland, Argentin... and more
Novartis Pharmaceuticals

Completed

Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis

Colombia, Panama, Peru, Brazil, Jordan, Malaysia, Mexico, Argentina
Novartis Pharmaceuticals

Completed

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) (EPOC)

Relapsing Remitting Multiple Sclerosis

Russian Federation
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)

Multiple Sclerosis

United States, Argentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo (GALA)

Relapsing Remitting Multiple Sclerosis

United States, Bulgaria, Croatia, Czechia, Estonia, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Poland, Romania, Russian Federation, South Africa, Ukraine, United Kingdom
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (CONCERTO)

Multiple Sclerosis

United States, Austria, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Estonia, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Latvia, Moldova, Republic of, Montenegro, North Macedonia and more
Immunic AG

Recruiting

Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis (ENSURE-2)

Multiple Sclerosis, Relapsing-Remitting

Turkey, United States, India, United Kingdom, Bosnia and Herzegovina, Estonia, Poland, Romania, Serbia, Ukraine, Armenia, Peru
Mapi Pharma Ltd.

Completed

A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Multiple Sclerosis, Relapsing-Remitting

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Estonia, Georgia, Israel, Moldova, Republic of, Russian Federation, Ukraine
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis. (ASCLEPIOS II)

Relapsing Multiple Scelrosis

United States, Austria, Belgium, Croatia, Germany, Taiwan, Canada, Czechia, Spain, Argentina, Australia, Peru, South Africa, United Kingdom, Bulgaria, Latvia, Lithuania, Russian Federation, India, Portugal, Italy, Turkey, Finland, France and more
Biogen

Completed

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a (ATTAIN)

Relapsing Multiple Sclerosis

United States, Croatia, Russian Federation, India, Spain, New Zealand, Canada, Belgium, Netherlands, Bulgaria, Serbia, Greece, Ukraine, Mexico, Georgia, Colombia, Germany, Poland, United Kingdom, Czech Republic, France, Chile, Romania, Eston... and more
Biogen

Completed

Efficacy and Safety Study of Peginterferon Beta-1a in Participants With Relapsing Multiple Sclerosis (ADVANCE)

Relapsing Multiple Sclerosis

United States, Germany, Russian Federation, India, New Zealand, Spain, Belgium, Colombia, Canada, Bulgaria, Serbia, Greece, Peru, Ukraine, Poland, United Kingdom, Croatia, France, Romania, Chile, Czech Republic, Mexico, Estonia, Georgia, Latv... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Spain, Czechia, Belgium, Italy, Canada, United Kingdom, Germany, Ireland, Turkey, Poland, Russian Federation, Ukraine, Croatia, Argentina, France, Belarus, Brazil, Mexico, Bosnia and Herzegovina, Bulgaria, Slovakia, S... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis

United States, Belgium, Czechia, Russian Federation, Serbia, Spain, Italy, Netherlands, Finland, Estonia, Brazil, France, Germany, Poland, Switzerland, Ukraine, Peru, Argentina, Lithuania, Slovakia, Portugal, Australia, Hungary, Tunisia, Bulgar... and more
Celgene

Completed

Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis (RADIANCE)

Relapsing Multiple Sclerosis

Spain, United States, United Kingdom, Croatia, Serbia, Belarus, Hungary, Bulgaria, Poland, Italy, Ukraine, Greece, Belgium, Georgia, Bosnia and Herzegovina, Moldova, Republic of, Romania, Russian Federation, Slovakia, South Africa and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) (FENhance)

Relapsing Multiple Sclerosis

United States, Mexico, Hungary, China, Germany, Italy, Peru, Poland, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Tunisia, Netherlands, Argentina, Georgia, Hong Kong, Kenya, Dominican Republic, Finland, North Macedonia, Serb...
Novartis Pharmaceuticals

Recruiting

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS (ALITHIOS)

Relapsing Multiple Sclerosis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Germany, Hungary, Poland, Portugal, Russian Federation, Slovakia, Spain, Denmark, France, Japan, Israel, Taiwan, Turkey, Czechia, Argentina, Estonia, United Kingdom, India, C... and more
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
EMD Serono Research & Development Institute, Inc.

Terminated

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

Relapsing Multiple Sclerosis

United States, Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Canada, Colombia, Croatia, Czechia, Estonia, Finland, France, Georgia, Germany, Hong Kong, Hungary, India, Israel, Italy, Korea, Republic of, M... and more
Novartis Pharmaceuticals

Completed

Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis

Relapsing Forms of Multiple Sclerosis

Germany, South Africa, Italy, United States, Austria, Belgium, Czechia, Egypt, Hungary, Malaysia, Turkey, Spain, Australia, Canada, France, Israel, Netherlands, Switzerland, Greece, Korea, Republic of, Romania, Russian Federation, United... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course

Relapsing Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom
AB Science

Recruiting

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

Progressive Multiple Sclerosis

Spain, Sweden, France, Greece, Italy, Poland, Russian Federation, Ukraine
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to Placebo (ARPEGGIO)

Primary Progressive Multiple Sclerosis

United States, Canada, Germany, Italy, Netherlands, Poland, Russian Federation, Spain, Ukraine, United Kingdom
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)

Multiple Sclerosis

United States, Brazil, Poland, United Kingdom, Turkey, Bulgaria, Belgium, Canada, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Ukraine, Mexico, Argentina
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, United Kingdom, Hungary, Bulgaria, Puerto Rico, Poland, Argentina, Brazil, Germany, Greece, Italy, Peru, Portugal, Russian Federation, Spain, Turkey, Ukraine, Israel, France, Switzerland, Colombia, Me... and more
Hoffmann-La Roche

Completed

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

Multiple Sclerosis, Primary Progressive

United States, Canada, Australia, Hungary, Brazil, Finland, Italy, Germany, Romania, Lithuania, France, Greece, Peru, Portugal, Spain, Switzerland, Bulgaria, Ukraine, Israel, Poland, Austria, New Zealand, Netherlands, Belgium, Mexico, United... and more
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (O'HAND)

Multiple Sclerosis, Primary Progressive

Canada, United States, Spain, Croatia, Serbia, Portugal, France, Tunisia, Mexico, Poland, Russian Federation, Australia, Belgium, Italy, United Kingdom, Ukraine, Bulgaria, Colombia, Georgia, Germany, Romania, New Zealand, Lebanon, Aus... and more
Sanofi

Recruiting

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS) (PERSEUS)

Primary Progressive Multiple Sclerosis

Spain, Italy, Turkey, India, Israel, Bulgaria, Mexico, Greece, Portugal, United States, Argentina, Australia, Austria, Belarus, Belgium, Canada, Chile, China, Colombia, Croatia, Czechia, Denmark, Estonia, France, Georgia, Germany, Hungary, Japan and more
Sanofi

Active, not recruiting

Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)

Secondary Progressive Multiple Sclerosis

United States, Argentina, Belgium, Canada, Czechia, France, Germany, Greece, India, Israel, Netherlands, Norway, Portugal, Turkey, United Kingdom, Japan, Austria, Bulgaria, China, Denmark, Finland, Italy, Lithuania, Poland, Romania, Russian... and more
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

Multiple Sclerosis

United States, Argentina, Poland, Canada, Australia, Belgium, Brazil, Denmark, France, Germany, Greece, Hungary, Italy, Peru, Portugal, Russian Federation, Spain, Switzerland, Turkey, Ukraine, United Kingdom
Biogen

Completed

Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex (SYNERGY)

Multiple Sclerosis

United States, Spain, Hungary, Serbia, Canada, France, Poland, Russian Federation, Netherlands, Czech Republic, Italy, United Kingdom
Actelion

Completed

Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis (OPTIMUM-LT)

Multiple Sclerosis

United States, Spain, Hungary, Israel, Portugal, Germany, Russian Federation, Belarus, Poland, Serbia, Latvia, Turkey, Croatia, Canada, Czechia, Bulgaria, Bosnia and Herzegovina, Finland, France, Georgia, Greece, Italy, Lithuania, Mexico and more
Celgene

Completed

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS) (SUNBEAM)

Multiple Sclerosis

United States, Spain, Czechia, Russian Federation, Portugal, Serbia, United Kingdom, New Zealand, Belarus, Bulgaria, Poland, Romania, Estonia, Germany, Sweden, Ukraine, Hungary, Croatia, Georgia, Bosnia and Herzegovina, Latvia, Li... and more
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)

Multiple Sclerosis

United States, Austria, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Russian Federation, Serbia, Spain, Sweden, Turkey, Ukraine, United Kingdom, Latvia
Actelion

Completed

Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis (OPTIMUM)

Multiple Sclerosis

United States, Belarus, Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Czechia, Finland, France, Georgia, Germany, Greece, Hungary, Israel, Italy, Latvia, Lithuania, Mexico, Poland, Portugal, Romania, Russian Federation, Serbia, S... and more
Hoffmann-La Roche

Active, not recruiting

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

Multiple Sclerosis

United States, Spain, Austria, Czechia, Italy, Hungary, Australia, Portugal, Serbia, Canada, Germany, United Kingdom, Poland, Romania, Croatia, Israel, Belgium, Bulgaria, Estonia, Switzerland, Mexico, Lithuania, New Zealand, France, Slo... and more
Ipsen

Terminated

Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 2 (CONTENT2)

Overactive Bladder | Urinary Incontinence

Spain, Israel, Russian Federation, France, Germany, Australia, Belgium, Brazil, United Kingdom, Mexico, Colombia, Chile, Argentina, Lithuania, Peru, Ukraine

Clinical Trials on Multiple Sclerosis-Relapsing-Remitting in Peru

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations